Evidence map›Paper›PMID 42530159›Full record

ArticleJournal of computational chemistry2026

Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.

Luis Felipe Hernández-Ayala, Gabriel Eduardo Guzmán-López, Annia Galano

Abstract read
In one paragraph

Article in Journal of computational chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Luis Felipe Hernández-AyalaDepartamento de Química, Universidad Autónoma Metropolitana Unidad Iztapalapa, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-3387-763X
Gabriel Eduardo Guzmán-LópezDepartamento de Química, Universidad Autónoma Metropolitana Unidad Iztapalapa, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-1443-4136
Annia GalanoDepartamento de Química, Universidad Autónoma Metropolitana Unidad Iztapalapa, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-1470-3060

Funding

SECIHTI CBF2023-2024-1141
6 · The paper itself

Abstract

Rett syndrome (RTT) is a severe neurodevelopmental disorder caused by mutations in the MECP2 gene. Although trofinetide is the first FDA-approved drug for RTT, its pharmacological mechanism remains unclear. We present a structure-based in silico workflow that integrates target prediction, molecular docking, and 100 ns molecular dynamics (MD) simulations to prioritize potential RTT-relevant targets. Candidate receptors were ranked using a comparative pleiotropic score (P

Indexed as

Molecular Dynamics SimulationRett SyndromeHumansMolecular Docking SimulationReceptors, GABA-AReceptors, GABA-Amolecular dockingmolecular dynamicsRett syndrometrofinetide

Identifiers

PMID42530159
PMCPMC13422011

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.